KRAS and lung cancer: BRAF mutations drive resistance to targeted inhibition of EGFR, while KRAS amplification leads to ALK kinase inhibitor resistance in EML4-ALK-drive lung cancer.40, 41 Similarly, downregulation of genes that negatively regulate the MAP kinase pathway have also been implicated in resistance.